Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
AbCellera Biologics Inc
ABCL
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$12.24
0.53
4.53%
Últ. Act.: Oct 22, 6:48 AM
$11.98
0.27
2.31%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
AbCellera Biologics Financials
AbCellera Biologics (ABCL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 50 percent decrease over losses of $(0.12) per share
Benzinga Newsdesk
PRO
AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year. The company reported
Benzinga Newsdesk
Earnings Scheduled For May 11, 2026
Benzinga Insights
What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.
Mohd Haider
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know
Benzinga Insights
PRO
AbCellera Biologics Q4 EPS $(0.03) Beats $(0.17) Estimate, Sales $44.900M Beat $6.351M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.17) by 82.04 percent. This is a 75 percent increase over losses of $(0.12) per share from
Benzinga Newsdesk
